On July 6, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, reported that Company’s Management will participate virtually in a fireside chat and in one-on-one investor meetings at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference, to be held virtually and in-person in New York, NY July 12-13 (Press release, Selecta Biosciences, JUL 6, 2022, View Source [SID1234616511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, July 13, 2022
Time: 1:00 p.m. ET
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On July 6, 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, before the U.S. financial markets open (Press release, Regeneron, JUL 6, 2022, View Source [SID1234616510]). The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at View Source To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

On July 6, 2022 Dr. Ettore Gilardoni, Head of Bio-MS at Philogen reported that it will present a poster entitled: A mass spectrometry-based method for the determination of in vivo biodistribution of small molecule-metal conjugates (Press release, Philogen, JUL 6, 2022, View Source [SID1234616509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gilardoni will also give a presentation on August 31st, entitled: Fibrioblast activation protein triggers selective release of drug payload from small molecule-drug conjugates in solid tumors.

On July 6, 2022 Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, reported that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors (Press release, Gnubiotics Sciences, JUL 6, 2022, View Source [SID1234616507]). The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well contributions from Gnubiotics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target especially in immunotherapy resistant patient cohorts. The sponsored project will advance GNU201 and GNU101, as potential first-in-class immunotherapeutics that steer immune responses to control growth in solid tumors expressing altered O-glycan profiles thus responding to a critical need in non-responding patients. The multi-year project which will include dose-finding and key translational studies, forms a core part of a broader preclinical development plan that will support an Investigational New Drug Application (IND).

"This support from Innosuisse and continued close collaboration with Prof. Michael Scharl`s group at the University Hospital Zürich provide further validation of our GLAAD platform, which holds great therapeutic potential for anti-PD-1 resistant and other non-responsive patient cohorts." stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer.

Gnubiotics presented compelling data recently at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting showing the effect of its glycopeptides platform in driving robust T-cell immune responses against anti-PD-1 resistant tumors in a colorectal cancer mouse model. Also announced recently, was a collaboration with the University of Pennsylvania to explore CAR-T therapy in combination with Gnubiotics’ glycopeptides to enhance CAR-T efficacy in solid tumors.

On July 6, 2022 EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, reported that Dr. Sid Kerkar, the company’s Vice President of Oncology, Research and Development, will participate in the In Vivo Engineering of Therapeutic Cells Summit organized by Hanson Wade on July 12-14, 2022 in Boston (Press release, EXUMA Biotechnology, JUL 6, 2022, View Source [SID1234616505]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the preclinical findings with EXUMA’s novel in vivo GCAR technology, which has the potential to overcome many of the barriers surrounding current ex vivo CAR therapies.

Our mission is centered on creating highly effective, safe, and durable treatments while reducing manufacturing complexity and costs, and increasing the speed and quality of delivery for the next generation of cell and gene therapies for cancer patients," said Sid Kerkar, M.D., VP Oncology, R&D.

EXUMA Biotech-Tuesday, July 12th, 2022

Participation: Pre-Conference Workshop

Title: Moving from Ex Vivo to In Vivo CAR T Engineering to Improve Clinical Performance & Accessibility

Details: In vivo CAR T has the potential to overcome challenges including production time, cost, and manufacturing delays, which could make this therapy more broadly available to patients.

This workshop will offer a deep-dive view into everything you need to know about CAR T and how to make the switch to the in vivo approach.

EXUMA Biotech Speaker: Dr. Sid Kerkar, EXUMA Biotech VP Oncology, R&D

Time: 10:00 AM ET

EXUMA Biotech-Wednesday, July 13th, 2022

Participation: Fireside Chat

Title: Industry Leader’s Fireside Chat: In Vivo Engineering of Therapeutic Cells as the Future of Cell & Gene Therapy

Details: This panel will explore what has inspired the move from ex vivo to in vivo therapies and will outline the advantages that in vivo cell and gene therapies offer.

Speakers will discuss next steps to streamline pre-clinical development to fast-track in vivo therapies to the clinic.

EXUMA Biotech Speaker: Dr. Sid Kerkar, EXUMA Biotech VP Oncology, R&D

Time: 9:30 AM ET

EXUMA Biotech- Thursday, July 14th, 2022

Participation: Roundtable Session

Title: Optimizing the In Vivo Approach: Considerations for Safety & Tolerability

Details: Dr. Kerkar will offer details on improving the safety and tolerability of in vivo therapies.

He’ll explore off target effects and will address issues of immunogenicity, integration, insertional mutagenesis, oncogenicity and pre-clinical models for toxicology.

EXUMA Biotech Speaker: Dr. Sid Kerkar, EXUMA Biotech VP Oncology, R&D

Time: 1:30 PM ET